as of 11-13-2026 3:38pm EST
Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. The company operates in one reportable segment, which includes all activities related to the development, manufacture, and sale of the Company's products, software, and other services.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BURLINGTON |
| Market Cap: | 2.3B | IPO Year: | 2020 |
| Target Price: | $11.17 | AVG Volume (30 days): | 4.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | -0.15 | EPS Growth: | 8.82 |
| 52 Week Low/High: | $1.90 - $10.21 | Next Earning Date: | 10-29-2026 |
| Revenue: | $97,610,000 | Revenue Growth: | 18.96% |
| Revenue Growth (this year): | 27.72% | Revenue Growth (next year): | 21.24% |
| P/E Ratio: | -44.37 | Index: | |
| Free Cash Flow: | -16048000.0 | FCF Growth: | N/A |
EVP, CFO
Avg Cost/Share
$7.00
Shares
50,000
Total Value
$350,000.00
Owned After
1,347,276
SEC Form 4
President & CEO
Avg Cost/Share
$7.01
Shares
90,600
Total Value
$634,924.80
Owned After
7,221,330
SEC Form 4
President & CEO
Avg Cost/Share
$10.02
Shares
35,790
Total Value
$358,615.80
Owned After
7,221,330
SEC Form 4
CAO and SVP, Finance
Avg Cost/Share
$8.75
Shares
10,114
Total Value
$88,446.93
Owned After
401,971
SEC Form 4
Chief Business Officer
Avg Cost/Share
$7.30
Shares
140,112
Total Value
$1,023,097.82
Owned After
1,490,295
SEC Form 4
CAO and SVP, Finance
Avg Cost/Share
$7.30
Shares
13,804
Total Value
$100,796.81
Owned After
401,971
SEC Form 4
Deputy General Counsel
Avg Cost/Share
$8.15
Shares
1,709
Total Value
$13,926.64
Owned After
305,166
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Doherty John N. | BFLY | EVP, CFO | Nov 11, 2026 | Sell | $7.00 | 50,000 | $350,000.00 | 1,347,276 | |
| DEVIVO JOSEPH | BFLY | President & CEO | Oct 30, 2026 | Sell | $7.01 | 90,600 | $634,924.80 | 7,221,330 | |
| DEVIVO JOSEPH | BFLY | President & CEO | Oct 6, 2026 | Sell | $10.02 | 35,790 | $358,615.80 | 7,221,330 | |
| Carlson Megan | BFLY | CAO and SVP, Finance | Oct 2, 2026 | Sell | $8.75 | 10,114 | $88,446.93 | 401,971 | |
| Cashman Steve | BFLY | Chief Business Officer | Sep 4, 2026 | Sell | $7.30 | 140,112 | $1,023,097.82 | 1,490,295 | |
| Carlson Megan | BFLY | CAO and SVP, Finance | Sep 4, 2026 | Sell | $7.30 | 13,804 | $100,796.81 | 401,971 | |
| Caezza Nicholas | BFLY | Deputy General Counsel | Sep 2, 2026 | Sell | $8.15 | 1,709 | $13,926.64 | 305,166 |
SEC 8-K filings with transcript text
Oct 29, 2026 · 100% conf.
1D
-2.54%
$7.22
Act: -17.54%
5D
-9.77%
$6.68
20D
-9.46%
$6.70
2 bfly-20261029xexx991.htm
Document
Exhibit 99.1
Butterfly Network Reports Third Quarter 2026 Financial Results
Beats High End of Quarterly Revenue and Adjusted EBITDA Guidance
•Delivered quarterly Revenue of $32.6 million, driven in part by Embedded revenue
•Recorded highest gross margin in Company history at 73%
•Management increases Full Year Revenue and Adjusted EBITDA Guidance
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE) -- Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.
Joseph DeVivo, Butterfly’s President, Chief Executive Officer and Chairman commented, “Our third quarter results came in ahead of guidance on both revenue and adjusted EBITDA, and we posted the highest gross margin in Butterfly’s history. We saw strength across our business. The enterprise pipeline is turning into signed deals, and achieving FedRAMP authorization puts larger federal opportunities on the table. Home & Community Care has also moved from building the program to executing it, with first revenue expected this November.”
DeVivo continued, “What excites me most is that our progress is compounding as we laid out. Our Ultrasound-on-Chip™ platform is taking Butterfly into entirely new categories, from brain-computer interfaces to physical AI. The first Embedded partner product is now on the market, and we have next-generation technology in motion. Every step forward expands the markets we can serve, and more than a decade of investment in this semiconductor platform is beginning to deliver on the vast potential we have expected.”
Recent Operational and Strategic Highlights:
•Butterfly Embedded™: Added three BCI partners, including the announcements of Merge Labs and Bridge Neurotech in the third quarter, while Mendaera became the first partner to launch a commercial product built on Butterfly technology on October 1, 2026.
•Compass AI™ and Enterprise Momentum: Closed five 7-figure and ten 6-figure TCV enterprise deals in the quarter.
•FedRAMP: Officially achieved FedRAMP authorization as expected, supporting federal and VA pipeline opportunities.
•Medical Education: Announced the Lighthouse program with VCOM, a multi-year partnership to equip every VCOM student with a Butterfly device and generate insights on POCUS use from medical school into residency.
•Butterfly Garden™: Signed five new partners, and DeepEcho became the first international and first maternal health partner application to go live on October 23, 2026.
•Home & Community Care: Entered the implementation phase to launch the first state, with scanning set to begin in November and initial revenue expected in the fourth quarter.
•International Expansion: Built momentum in Brazil, and added a new distribution partner in Taiwan.
•Innovation Roadmap: Advanced development of the Apollo chip on schedule; prepared a limited release of wearable research devices for Embedded partners; and continue preparations to launch a next-generation product powered by the P5.1 chip in early 2027.
Three Months Ended September 30, 2026 Financial Results
Revenue: Total revenue was $32.6 million, representing growth of 52% from $21.5 million in the third quarter of 2025. U.S. revenue was $27.5 million, up 71% from prior year, primarily driven by revenue from our various Butterfly Embedded™ partnerships, including our co-development partnership with Midjourney, as well as increased probe sales volume to our health system, distributor, and eCommerce customers. International revenue decreased 5% year-over-year to $5.1 million, largely resulting from decreased probe sales to our global health partners.
Gross margin: Gross profit was $23.8 million versus a gross loss of $3.8 million in the prior year period, and adjusted gross profit was $23.8 million versus $13.7 million in the prior year period. Total gross margin, on a GAAP basis, was 73.0% compared to (17.5)% in the prior year period, and adjusted gross margin increased to 73.0% from 63.9% in the prior year period. The $27.6 million increase in GAAP gross margin is due in part to the $17.4 million write-down of excess and obsolete inventory that was recognized during the prior year period, which is excluded from adjusted gross profit and adjusted gross margin. The remainder of the increase in GAAP gross margin, as well as the $10.1 million increase in adjusted gross margin, was primarily due to the relatively higher margin return on our Butterfly Embedded™ licensing revenue, as compared to our core business offerings, as well as our increased probe sales volume in the current year.
Operating expenses: Operating expenses were $37.4 million, up 19% from $31.4 million in the prior year period. Total operating expenses excluding stock-based compensation and other expenses wer
Jul 30, 2026 · 100% conf.
1D
-2.68%
$7.95
Act: -12.97%
5D
-9.77%
$7.37
Act: +1.59%
20D
-9.55%
$7.39
2 bfly-20260730xexx991.htm
Document
Exhibit 99.1
Butterfly Network Reports Second Quarter 2026 Financial Results
Delivered Record Revenue and Adjusted EBITDA Loss Above Guidance
•Raised full year Revenue and Improved Adjusted EBITDA Guidance
•Delivered quarterly Revenue of $32.6 million in Q2, representing 39% YoY growth
•Delivered 71% Gross Margin, up 770 bps
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE) -- Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced financial results for the second quarter ended June 30, 2026, and provided a business update.
Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, "Butterfly delivered another outstanding quarter, exceeding the high end of our guidance while achieving record revenue, gross margin and adjusted EBITDA. Just as important, the world got to see what Ultrasound-on-Chip™ is capable of as two Embedded partners unveiled entirely new applications being built on our platform. It's an exciting milestone for Butterfly and a validation of the opportunity we've believed in for years."
DeVivo continued, "As those announcements captured global attention, they also highlighted something bigger: Butterfly has evolved into a multi-engine growth company. Our semiconductor platform is expanding into new markets through Butterfly Embedded; our POCUS business is building a larger enterprise opportunity through software, medical education and government; and Home & Community Care is transitioning from pilot to commercialization. Together, these growth engines reinforce one another and continue to expand our long-term opportunity."
Recent Operational and Strategic Highlights:
•Butterfly Embedded™: Added two new partners to the Embedded portfolio, totaling 11 partners, with Midjourney and Aleph Neuro unveiling the groundbreaking applications they’re building with Butterfly's Ultrasound-on-Chip™ platform.
•Compass AI™ and Enterprise Momentum: Signed six new enterprise software agreements and expanded the Compass AI software pipeline meaningfully year over year.
•FedRAMP Progress: Received provisional authorization to sell across the U.S. Department of Veterans Affairs and remains on track to achieve FedRAMP certification in the third quarter of 2026.
•Medical Education Expansion: Closed four additional medical education partners in the quarter, including entering a long-term strategic partnership with VCOM to support and gain insights following physicians from medical school to residency and clinical practice.
•Butterfly Garden™: Added a new partner focused on precision needle-guidance AI and expect three existing partner tools to become commercially available by year-end.
•Home & Community Care: Prepared for first commercial implementation in the second half of 2026, with revenue expected in the fourth quarter.
•International Expansion: Received regulatory authorization in Brazil, opening one of the world's largest and fastest-growing ultrasound markets.
Three Months Ended June 30, 2026 Financial Results
Revenue: Total revenue was $32.6 million, representing growth of 39% from $23.4 million in the second quarter of 2025. U.S. revenue was $27.6 million, up 57% from prior year, primarily driven by revenue from our Butterfly
Embedded™ partnerships, including our co-development partnership with Midjourney, as well as increased probe sales volume to our health system, medical school, and eCommerce customers. International revenue decreased 14% year-over-year to $5.0 million, largely resulting from decreased probe sales to our international distribution partners during the second quarter, although this decrease was partially offset by our recent commercial expansion into the Brazilian medical device market.
Gross margin: Gross profit was $23.3 million versus gross profit of $14.9 million in the prior year period. Gross margin increased to 71.4% compared to 63.7% in the prior year period. This increase was primarily due to the relatively higher margin return on our Butterfly Embedded™ licensing revenue, as compared to our core business offerings, as well as a reduction in software amortization costs for our historic software development investments.
Operating expenses: Operating expenses were $37.0 million, up 19% from $31.0 million in the prior year period. Total operating expenses excluding stock-based compensation and other expenses were $26.3 million, compared to $23.1 million in the second quarter of 2025, largely reflecting increased headcount in the current year from investments we've made in our internal capabilities throughout the past 12 months to support revenue growth as well as our product and software development projects.
Net loss: Net loss was $12.9 million, compared to $13.8 million in the prior year period.
Adjusted EBITDA: Adjusted EBITDA loss was $1.4 million, an
Apr 30, 2026
2 bfly-20260430xexx991.htm
Document
Exhibit 99.1
Butterfly Network Reports First Quarter 2026 Financial Results
Delivered Revenue Above Consensus and Beat Adjusted EBITDA Guidance
•Reaffirmed full year Revenue and Adjusted EBITDA Guidance
•Delivered quarterly Revenue of $26.5 million in Q1, representing 25% YoY growth.
•Delivered 69% Gross Margin up 600 bps and Adjusted EBITDA of ($6.1M) up 32% YoY
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE) -- Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.
Joseph DeVivo, Butterfly’s President, Chief Executive Officer and Chairman commented, “Butterfly opened the year with another strong quarter, coming in above consensus with 25% revenue growth and continued gross margin improvement. We are executing with discipline while continuing to invest in the vast opportunity ahead.”
DeVivo continued, “Our business is starting to come together around three growth engines. Point-of-care ultrasound is scaling globally. Home & Community Care is extending that capability into the patient environment. And Butterfly Embedded is expanding our technology beyond medical ultrasound into new modalities. These are not separate opportunities. They are all part of the same Butterfly platform, a single system that is beginning to work together and compound over time. We are still early, but the direction is clear, and we are building with focus and discipline to drive long-term growth.”
Recent Operational and Strategic Highlights:
•Gestational Age AI Tool: Received FDA clearance and initiated rollout of blind-sweep AI tool for rapid fetal age estimation across U.S. and global health markets.
•Butterfly Garden Ecosystem: Added two new partners, bringing the portfolio total to 30, while continuing to progress toward additional commercial-ready applications.
•Compass AI™ and Enterprise Momentum: Closed first enterprise deal of the year and drove significant growth in the software pipeline since launching the next generation Compass AI solution.
•Global Market Expansion: Advancing entry into new markets across the Americas and Asia, including high-growth regions such as Brazil, with iQ3 expansion in multiple countries.
•Home & Community Care: Progressing toward first commercial agreement in the first half of 2026, with initial statewide deployment expected in the third quarter.
•Butterfly Embedded™: Signed ninth company to the portfolio as of April 2026 and made meaningful development progress with existing partners.
•Apollo Platform Development: Continued advancement of next-generation semiconductor architecture designed to significantly increase data processing and compute performance.
Three Months Ended March 31, 2026 Financial Results
Revenue: Total revenue was $26.5 million, representing growth of 25% from $21.2 million in the first quarter of 2025. U.S. revenue was $21.4 million, up 25% from prior year, primarily driven by revenue from our Butterfly Embedded™ partnerships, including our co-development partnership with Midjourney. International revenue increased 23% year-over-year to $5.2 million, largely resulting from increased probe sales in the current year to
our distribution partners. Both our U.S. and international revenue also benefited from favorable shifts in our product sales mix towards our higher-priced iQ3 probes.
Gross margin: Gross profit was $18.3 million versus gross profit of $13.4 million in the prior year period. Gross margin increased to 68.9% compared to 63.0% in the prior year period. This increase was primarily due to the relatively higher margin return on our Butterfly Embedded™ licensing revenue, as compared to our core business offerings, as well as a reduction in software amortization costs for our historic software development investments.
Operating expenses: Operating expenses were $32.2 million, up 1% from $31.8 million in the prior year period. Total operating expenses excluding stock-based compensation and other expenses were $26.2 million, compared to $24.9 million in the first quarter of 2025, largely reflecting increased headcount in the current year from investments we've made in our internal capabilities throughout the past 12 months to support revenue growth as well as higher professional services costs.
Net loss: Net loss was $12.7 million, compared to $14.0 million in the prior year period.
Adjusted EBITDA: Adjusted EBITDA loss was $6.1 million, compared to $9.1 million in the prior year period.
EPS: EPS was $(0.05), compared to $(0.06) in the prior year period.
Adjusted EPS: Adjusted EPS was $(0.03), compared to $(0.04) in the prior year period.
Cash and cash equivalents: Cash and cash equivalents were $138.0 million as of March 31, 2026.
Guidance
Reaffirmed revenue guidance and
See how BFLY stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "BFLY Butterfly Network Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.